Plus   Neg

SAGE Therapeutics Inc. (SAGE) Is Soaring To A New High On Study Results

SAGE Therapeutics Inc. (SAGE) announced Thursday morning that its Phase 2 study of SAGE-217 showed a statistically significant mean reduction in the Hamilton Rating Scale for Depression.

SAGE Therapeutics has gapped open dramatically higher this morning and is now up 71.24 at $163.14 on above average volume. The stock has soared to a new high for the year.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT